Skip to main content

Drug Interactions between tovorafenib and Vraylar

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cariprazine tovorafenib

Applies to: Vraylar (cariprazine) and tovorafenib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inducers of CYP450 3A4 is expected to alter the pharmacokinetics of cariprazine and its major active metabolites. However, the interaction has not been studied; therefore, the net effect on active drug and metabolites is unclear. Cariprazine is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2D6 to desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR). DCAR is further metabolized to DDCAR by CYP450 3A4 and 2D6, and DDCAR is then metabolized by CYP450 3A4 to a hydroxylated metabolite. Both DCAR and DDCAR have in vitro receptor binding profiles similar to the parent drug and are considered pharmacologically equipotent to cariprazine.

MANAGEMENT: Concomitant use of cariprazine with CYP450 3A4 inducers has not been evaluated and is not recommended.

References

  1. (2022) "Product Information. Vraylar (cariprazine)." Allergan Inc
  2. (2022) "Product Information. Reagila (cariprazine)." Recordati Pharmaceuticals Ltd
  3. (2022) "Product Information. Reagila (cariprazine)." Gedeon Richter Australia Pty Ltd
  4. (2022) "Product Information. Vraylar (cariprazine)." AbbVie Corporation
View all 4 references

Drug and food interactions

Moderate

cariprazine food

Applies to: Vraylar (cariprazine)

Grapefruit juice can increase the blood levels of cariprazine. This may increase side effects such as extrapyramidal symptoms, cognitive and motor impairment, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leucopenia, neutropenia, seizures, and dysphagia. You should avoid the consumption of grapefruit and grapefruit juice during treatment with cariprazine. Talk to your doctor or pharmacist if you have questions on this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.